Monitoring new psychoactive substances (NPS) in The Netherlands: Data from the drug market and the Poisons Information Centre

Drug and Alcohol Dependence

Volumn 147, Issue , 2015, Pages 109-115

  Hondebrink, Laura ^a   Nugteren van Lonkhuyzen, Johanna J ^a   Van Der Gouwe, Daan ^b   Brunt, Tibor M ^b,c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NETHERLANDS INSTITUTE OF MENTAL HEALTH AND ADDICTION   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

2C B; 4 FA; 6 APB; Clinical; Methoxetamine; Toxicology

Indexed keywords

2,5 DIMETHOXY 4 CHLOROAMPHETAMINE; 2,5 DIMETHOXY 4 ETHYLPHENETHYLAMINE; 2,5 DIMETHOXY 4 IODOPHENETHYLAMINE; 2,5 DIMETHOXY 4 METHYLPHENETHYLAMINE; 2,5 DIMETHOXY 4 PROPYLPHENETHYLAMINE; 2,5 DIMETHOXY 4 PROPYLTHIOPHENETHYLAMINE; 3 FLUOROMETHCATHINONE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 (2 AMINOPROPYL)BENZOFURAN; 4 BROMO 2,5 DIMETHOXYPHENETHYLAMINE; 4 FLUOROAMPHETAMINE; 4 FLUOROMETHAMPHETAMINE; 4 METHYLMETHCATHINONE; 4' METHYLMETHCATHINONE; 5 (2 AMINOPROPYL) 2,3 DIHYDROBENZOFURAN; 5 (2 AMINOPROPYL)BENZOFURAN; 5 METHOXY N,N METHOXYTRYPTAMINE; 6 (2 AMINOPROPYL) 2,3 DIHYDROBENZOFURAN; 6 (2 AMINOPROPYL)BENZOFURAN; AMPHETAMINE; BUPHEDRONE; COCAINE; ETHYLONE; KETAMINE; LYSERGIDE; METHOXETAMINE; METHYLONE; N,N DIMETHYLTRYPTAMINE; PSYCHOTROPIC AGENT; UNCLASSIFIED DRUG; STREET DRUG;

AGITATION; ARTICLE; CARDIOVASCULAR DISEASE; DRUG INTOXICATION; DRUG MARKETING; DRUG SURVEILLANCE PROGRAM; HALLUCINATION; HUMAN; HYPERTENSION; MENTAL DISEASE; NETHERLANDS; NEUROLOGIC DISEASE; TACHYCARDIA; ADOLESCENT; ADULT; DRUG USE; EPIDEMIOLOGY; FEMALE; INFORMATION CENTER; MALE; POISON CENTER; STATISTICS; TRENDS; YOUNG ADULT;

ADOLESCENT; ADULT; DRUG USERS; FEMALE; HUMANS; INFORMATION CENTERS; MALE; NETHERLANDS; POISON CONTROL CENTERS; PSYCHOTROPIC DRUGS; STATISTICS AS TOPIC; STREET DRUGS; YOUNG ADULT;

EID: 84921030276     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2014.11.033     Document Type: Article

References (57)

1. Ambrose J.B., Bennett H.D., Lee H.S., Josephson S.A. Cerebral vasculopathy after 4-bromo-2,5-dimethoxyphen-ethylamine ingestion. Neurologist 2010, 16:199-202.
2. Barratt M.J., Ferris J.A., Winstock A.R. Use of Silk Road, the online drug marketplace, in the United Kingdom, Australia and the United States. Addiction 2014, 109:774-783.
3. Blanckaert P., van Amsterdam J., Brunt T., van den Berg J., Van Durme F., Maudens K., van Bussel J. 4-Methyl-amphetamine: a health threat for recreational amphetamine users. J. Psychopharmacol. 2013, 27:817-822.
4. Brandt S.D., Sumnall H.R., Measham F., Cole J. Analyses of second-generation 'legal highs' in the UK: initial findings. Drug Test. Anal. 2010, 2:377-382.
5. Brunt T.M., Niesink R.J. The Drug Information and Monitoring System (DIMS) in The Netherlands: implementation, results, and international comparison. Drug Test. Anal. 2011, 3:621-634.
6. Brunt T.M., Poortman A., Niesink R.J., van den Brink W. Instability of the ecstasy market and a new kid on the block: mephedrone. J. Psychopharmacol. 2011, 25:1543-1547.
7. Brunt T.M., Koeter M.W., Niesink R.J., van den Brink W. Linking the pharmacological content of ecstasy tablets to the subjective experiences of drug users. Psychopharmacology (Berl.) 2012, 220:751-762.
8. Burns L., Roxburgh A., Matthews A., Bruno R., Lenton S., Van Buskirk J. The rise of new psychoactive substance use in Australia. Drug Test. Anal. 2014, 6:846-849.
9. Caudevilla-Gálligo F., Riba J., Ventura M., González D., Farré M., Barbanoj M.J., Bouso J.C. 4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects. J. Psychopharmacol. 2012, 26:1026-1035.
10. Chan W.L., Wood D.M., Hudson S., Dargan P.I. Acute psychosis associated with recreational use of benzofuran 6-(2-aminopropyl)benzofuran (6-APB) and cannabis. J. Med. Toxicol. 2013, 9:278-281.
11. Coppola M., Mondola R. 3,4-Methylenedioxypyrovalerone (MDPV): chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online. Toxicol. Lett. 2012, 208:12-15.
12. Corazza O., Schifano F., Simonato P., Fergus S., Assi S., Stair J., Corkery J., Trincas G., Deluca P., Davey Z., Blaszko U., Demetrovics Z., Moskalewicz J., Enea A., di Melchiorre G., Mervo B., di Furia L., Farre M., Flesland L., Pasinetti M., Pezzolesi C., Pisarska A., Shapiro H., Siemann H., Skutle A., di Melchiorre G., Sferrazza E., Torrens M., van der Kreeft P., Zummo D., Scherbaum N. Phenomenon of new drugs on the Internet: the case of ketamine derivative methoxetamine. Hum. Psychopharmacol. 2012, 27:145-149.
13. Corazza O., Assi S., Schifano F. From Special K"to Special M": the evolution of the recreational use of ketamine and methoxetamine. CNS Neurosci. Ther. 2013, 19:454-460.
14. Coulson C., Caulkins J.P. Scheduling of newly emerging drugs: a critical review of decisions over 40 years. Addiction 2012, 107:766-773.
15. de Boer D., Gijzels M.J., Bosman I.J., Maes R.A. More data about the new psychoactive drug 2C-B. J. Anal. Toxicol. 1999, 23:227-228.
16. de Jong B., van Vuren A.J., Niesink R.J., Brunt T.M. A patient in a methoxetamin-induced dissociative psychosis. Ned. Tijdschr. Geneeskd. 2014, 158(0):A7358. (Dutch).
17. Elliott S., Evans J. A 3-year review of new psychoactive substances in casework. Forensic Sci. Int. 2014, 243:55-60.
18. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Monitoring New Drugs 2006, EMCDDA, Lisbon.
19. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Early-warning System on New Psychoactive Substances-Operating Guidelines 2007, EMCDDA, Europol, Lisbon, Portugal.
20. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) General Population Surveys, Methods and Definitions 2007, Available at 〈http://www.emcdda.europa.eu/stats07/GPS/methods〉 (Accessed on the 11th of November 2014).
21. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Annual Report 2014 2014, Available at 〈http://www.emcdda.europa.eu/attachements.cfm/att_228272_EN_TDAT14001ENN.pdf〉 (Accessed on the 6th of July 2014).
22. Gine C.V., Espinosa I.F., Vilamala M.V. New psychoactive substances as adulterants of controlled drugs. A worrying phenomenon?. Drug Test. Anal. 2014, 6:819-824.
23. Global Drug Survey, GDS, 2014. Available at: http://www.globaldrugsurvey.com/facts-figures/theglobal-drug-survey-2014-findings/. Accessed on the 18th of July 2014.
24. Goossens F.X., Frijns T., van Hasselt N.E., van Laar M.W. Het Grote Uitgaansonderzoek 2013 2014, Trimbos Institute, Utrecht, The Netherlands.
25. Green A.R., Nutt D.J. Pharmacology should be at the centre of all preclinical and clinical studies on new psychoactive substances (recreational drugs). J. Psychopharmacol. 2014, 28:711-718.
26. Helander A., Backberg M., Hulten P., Al-Saffar Y., Beck O. Detection of new psychoactive substance use among emergency room patients: results from the Swedish STRIDA project. Forensic Sci. Int. 2014, 243:23-29.
27. Hill S.L., Harbon S.C., Coulson J., Cooper G.A., Jackson G., Lupton D.J., Vale J.A., Thomas S.H. Methoxetamine toxicity reported to the National Poisons Information Service: clinical characteristics and patterns of enquiries (including the period of the introduction of the UK's first Temporary Class Drug Order). Emerg. Med. J. 2014, 31:45-47.
28. Home Office Statistics Drug Misuse: Findings from the 2012 to 2013 Crime Survey for England and Wales 2013, Available at 〈https://www.gov.uk/government/publications/drug-misuse-findings-from-the-2012-to-2013-csew/drug-misusefindings-from-the-2012-to-2013-crime-survey-for-england-and-wales〉.
29. Huang H.H., Bai Y.M. Persistent psychosis after ingestion of a single tablet of '2C-B'. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:293-294.
30. Hughes B., Winstock A.R. Controlling new drugs under marketing regulations. Addiction 2012, 107:1894-1899.
31. Imbert L., Boucher A., Delhome G., Cueto T., Boudinaud M., Maublanc J., Dulaurent S., Descotes J., Lachâtre G., Gaulier J.M. Analytical findings of an acute intoxication after inhalation of methoxetamine. J. Anal. Toxicol. 2014, 38:410-415.
32. Kriikku P., Wilhelm L., Schwarz O., Rintatalo J. New designer drug of abuse: 3,4-methylenedioxy-pyrovalerone (MDPV), findings from apprehended drivers in Finland. Forensic Sci. Int. 2011, 210:195-200.
33. Loeffler G., Craig C.J. Methoxetamine misuse and toxicity. Stud. Alcohol Drugs 2013, 74:816-817.
34. Maxwell J.C. Psychoactive substances-some new, some old: a scan of the situation in the U.S. Drug Alcohol Depend. 2014, 134:71-77.
35. Miotto K., Striebel J., Cho A.K., Wang C. Clinical and pharmacological aspects of bath salt use: a review of the literature and case reports. Drug Alcohol Depend. 2013, 132:1-12.
36. Murray D.B., Potts S., Haxton C., Jackson G., Sandilands E.A., Ramsey J., Puchnarewicz M., Holt D.W., Johnston A., Nicholas Bateman D., Dear J.W. 'Ivory wave' toxicity in recreational drug users; integration of clinical and poisons information services to manage legal high poisoning. Clin. Toxicol. 2012, 50:108-113.
37. Prosser J.M., Nelson L.S. The toxicology of bath salts: a review of synthetic cathinones. J. Med. Toxicol. 2012, 8:33-42.
38. Ricaurte G.A., McCann U.D. Recognition and management of complications of new recreational drug use. Lancet 2005, 365:2137-2145.
39. Rohrich J., Becker J., Kaufmann T., Zorntlein S., Urban R. Detection of the synthetic drug 4-fluoroamphetamine (4-FA) in serum and urine. Forensic Sci. Int. 2012, 215:3-7.
40. Rust K.Y., Baumgartner M.R., Dally A.M., Kraemer T. Prevalence of new psychoactive substances: a retrospective study in hair. Drug Test. Anal. 2012, 4:402-408.
41. Salomone A., Luciano C., Di Corcia D., Gerace E., Vincenti M. Hair analysis as a tool to evaluate the prevalence of synthetic cannabinoids in different populations of drug consumers. Drug Test. Anal. 2014, 6:126-134.
42. Schifano F., Deluca P., Baldacchino A., Peltoniemi T., Scherbaum N., Torrens M., Farre M., Flores I., Rossi M., Eastwood D., Guionnet C., Rawaf S., Agosti L., Di Furia L., Brigada R., Majava A., Siemann H., Leoni M., Tomasin A., Rovetto F., Ghodse A.H. Drugs on the web: the Psychonaut 2002 EU project. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30:640-646.
43. Sein Anand J., Wiergowski M., Barwina M., Kaletha K. Accidental intoxication with high dose of methoxetamine (MXE)-a case report. Przegl. Lek. 2012, 69:609-610.
44. Shields J.E., Dargan P.I., Wood D.M., Puchnarewicz M., Davies S., Waring W.S. Methoxetamine associated reversible cerebellar toxicity: three cases with analytical confirmation. Clin. Toxicol. 2012, 50:438-440.
45. van Amsterdam J., Nutt D., van den Brink W. Generic legislation of new psychoactive drugs. J. Psychopharmacol. 2013, 27:317-324.
46. van der Gouwe D. DIMS Jaarbericht, Update 2012 2013, Trimbos Institute, Utrecht, The Netherlands, Available at 〈http://www.trimbos.nl/webwinkel/~/media/files/gratis%20downloads/af1236%20dims%20jaarbericht%20update%202012_web.ashx〉.
47. van der Gouwe D. DIMS Jaarbericht, Update 2013 2014, Trimbos Institute, Utrecht, The Netherlands, Available at 〈http://www.trimbos.nl/webwinkel/~/media/files/gratis%20downloads/af1307%20dims%20jaarbericht%202013.ashx〉.
48. van Laar M.W., Cruts A.A.N., van Ooyen-Houben M.M.J., Meijer R.F., Croes E.A., Ketelaars A.P.M., Verdurmen J.E.E., Brunt T. Netherlands national drug monitor. NDM Annual Report 2012 2013, Trimbos Institute, Utrecht, The Netherlands.
49. van Laar M.W., van Ooyen-Houben M.M.J., Cruts A.A.N., Meijer R.F., Croes E.A., Ketelaars A.P.M., van der Pol P.M. Netherlands national drug monitor. NDM Annual Report 2013 2014, Trimbos Institute, Utrecht, The Netherlands.
50. Vevelstad M., Øiestad E.L., Middelkoop G., Hasvold I., Lillend P., Delaveris G.J., Eggen T., Mørland J., Arnestad M. The PMMA epidemic in Norway: comparison of fatal and non-fatal intoxications. Forensic Sci. Int. 2012, 219:151-157.
51. Vogels H., Brunt T.M., Rigter S., van Dijk P., Vervaeke H., Niesink R.J. Content of ecstasy in The Netherlands: 1993-2008. Addiction 2009, 104:2057-2066.
52. Ward J., Rhyee S., Plansky J., Boyer E. Methoxetamine: a new ketamine analog and growing health-care concern. Clin. Toxicol. 2011, 49:874-875.
53. Westwell A.D., Hutchings A., Caldicott D.G. The identification and chemical characterization of a new arylcyclohexylamine, methoxetamine, using a new Emergency Department toxicosurveillance tool. Drug Test. Anal. 2013, 5:203-207.
54. Winstock A.R., Mitcheson L.R., Deluca P., Davey Z., Corazza O., Schifano F. Mephedrone, new kid for the chop?. Addiction 2011, 106:154-161.
55. Wood D.M., Davies S., Puchnarewicz M., Johnston A., Dargan A., Dargan P.I. Acute toxicity associated with the recreational use of the ketamine derivative methoxetamine. Eur. J. Clin. Pharmacol. 2012, 68:853-856.
56. Wood K.E. Acute toxicity associated with the recreational use of the ketamine derivative methoxetamine. Eur. J. Clin. Pharmacol. 2013, 68:853-856.
57. Zamengo L., Frison G., Bettin C., Sciarrone R. Understanding the risks associated with the use of new psychoactive substances (NPS): high variability of active ingredients concentration, mislabelled preparations, multiple psychoactive substances in single products. Toxicol. Lett. 2014, 229:220-228.